Holen Sie sich die Stockscreener-App
676.77
1.13%
7.575
Schlusskurs vom Vortag:
$669.20
Offen:
$671.46
24-Stunden-Volumen:
306.54K
Relative Volume:
0.70
Marktkapitalisierung:
$18.93B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$460.40M
KGV:
42.57
EPS:
15.8963
Netto-Cashflow:
$711.00M
1W Leistung:
+8.73%
1M Leistung:
+9.35%
6M Leistung:
+60.61%
1J Leistung:
+13.46%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$614.98
$684.52
52-Wochen-Spanne:
$373.00
$684.52
Medpace Holdings Inc Stock (MEDP) Company Profile
Firmenname
Medpace Holdings Inc
Sektor
Branche
Telefon
(513) 579-9911
Adresse
5375 MEDPACE WAY, CINCINNATI, OH
Compare MEDP vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MEDP
Medpace Holdings Inc
|
676.77 | 18.93B | 2.68B | 460.40M | 711.00M | 15.90 |
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Medpace Holdings Inc Stock (MEDP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-30 | Fortgesetzt | UBS | Neutral |
| 2026-07-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2026-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2026-03-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2026-03-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-18 | Hochstufung | TD Cowen | Sell → Hold |
| 2026-02-13 | Hochstufung | Jefferies | Hold → Buy |
| 2026-02-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-02 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-09-03 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-29 | Herabstufung | UBS | Neutral → Sell |
| 2025-07-23 | Herabstufung | TD Cowen | Hold → Sell |
| 2025-06-24 | Eingeleitet | Barclays | Equal Weight |
| 2025-04-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-04-14 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-24 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-27 | Herabstufung | UBS | Buy → Neutral |
| 2024-09-25 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-01 | Eingeleitet | Truist | Hold |
| 2024-05-29 | Eingeleitet | TD Cowen | Buy |
| 2024-05-28 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-18 | Eingeleitet | Deutsche Bank | Hold |
| 2024-02-15 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-05-08 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-27 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-07 | Eingeleitet | UBS | Sell |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-10-02 | Hochstufung | Truist | Hold → Buy |
| 2020-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2020-05-13 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-04-30 | Hochstufung | SunTrust | Sell → Hold |
| 2020-04-20 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-03-17 | Herabstufung | SunTrust | Hold → Sell |
| 2020-01-27 | Herabstufung | SunTrust | Buy → Hold |
| 2018-10-31 | Hochstufung | SunTrust | Hold → Buy |
| 2018-09-17 | Eingeleitet | SunTrust | Hold |
| 2018-07-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-11-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2017-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2017-07-10 | Herabstufung | KeyBanc Capital Mkts | Overweight → Sector Weight |
Alle ansehen
Medpace Holdings Inc Aktie (MEDP) Neueste Nachrichten
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Zacks Investment Research
All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy - Zacks Investment Research
Medpace: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 12 October - Investing.com Canada
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 12 October - Investing.com UK
At $166.73 a share, Medpace (MEDP) EVP Susan E. Burwig exercised options for 3,000 shares. - Stock Titan
CON vs. MEDP: Which Stock Should Value Investors Buy Now? - Zacks Investment Research
Medpace (MEDP) Dips More Than Broader Market: What You Should Know - Zacks Investment Research
At $166.73 per share, Medpace (MEDP) EVP Susan E. Burwig exercises options for 2,000 shares. - Stock Titan
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors - Zacks Investment Research
After converting stock units into 28 shares, Medpace (MEDP) director McCarthy holds 12,303 shares directly. - Stock Titan
After a 32-share grant conversion, Medpace (MEDP) director Kraft holds 987 shares directly. - Stock Titan
After a 36-share conversion, Medpace (MEDP) director Carley holds 27,861 common shares. - Stock Titan
Medpace Holdings CEO August Troendle sells $30.3m in stock By Investing.com - Investing.com South Africa
Medpace Holdings CEO August Troendle sells $30.3m in stock By Investing.com - Investing.com Nigeria
Form 4 Medpace Holdings Inc For: 2 October By Investing.com - Investing.com Nigeria
Form 4 Medpace Holdings Inc For: 2 October By Investing.com - Investing.com South Africa
Medpace Holdings CEO August Troendle sells $30.3m in stock - Investing.com
Form 4 Medpace Holdings Inc For: 2 October By Investing.com - Investing.com Australia
Two days of CEO share sales at Medpace (MEDP) were executed through an open-window limit order. - Stock Titan
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts - Zacks Investment Research
At about $620 a share, Medpace (MEDP) CEO sells stock on two dates: 2,410 shares and 154 shares - Stock Titan
Form 13D/A Medpace Holdings For: 28 September By Investing.com - Investing.com Nigeria
Medpace Holdings CEO August J. Troendle sells $6.75m in stock - Investing.com
Medpace Holdings CEO August Troendle sells $44.4m stock - Investing.com
Form 4 Medpace Holdings Inc For: 27 September By Investing.com - Investing.com India
Form 4 Medpace Holdings Inc For: 27 September By Investing.com - Investing.com UK
CEO sells shares on two days at Medpace (MEDP); a separate entry lists 4,733,019 indirectly held shares. - Stock Titan
After a 13,059-share sale, August Troendle reports a stake in Medpace (MEDP). - Stock Titan
Medpace (MEDP) CEO sold 49,018 shares on Sept. 22 at a $628.11 average price. - Stock Titan
MEDP FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class ActionMEDP - TMX Newsfile
MEDP DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Medpace Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 8 Deadline in Securities Class ActionMEDP - TMX Newsfile
Medpace (MEDP) Outperforms Broader Market: What You Need to Know - Zacks Investment Research
Medpace (NASDAQ: MEDP) CEO sells shares, holds 504,273 directly - stocktitan.net
Medpace Holdings, Inc.Common Stock (Nasdaq:MEDP) Price Chart - The Chronicle-Journal
Medpace Holdings (MEDP) CEO sells stock in two $620-range trades - stocktitan.net
Medpace Holdings (MEDP) insider exercises 3,000 options - stocktitan.net
Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 5 Years - Benzinga
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Encourages Shareholders to Reach Out - ACCESS Newswire
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Medpace Holdings, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMEDP - Eastern Progress
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & Korsinsky - Eastern Progress
Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - Eastern Progress
Medpace Holdings, Inc. (MEDP) Stock Analysis: Evaluating the Healthcare Giant’s Growth Potential - DirectorsTalk Interviews
MEDP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Medpace Holdings, Inc. Securities LawsuitContact The Gross Law Firm - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Medpace Holdings Inc. (MEDP) Key Financial Ratios – Valuation, Profitability & More - Value Research
Medpace Holdings, Inc. (MEDP), Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Finanzdaten der Medpace Holdings Inc-Aktie (MEDP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Medpace Holdings Inc-Aktie (MEDP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BURWIG SUSAN E | Exec. VP, Operations |
Oct 21 '26 |
Option Exercise |
166.73 |
2,700 |
450,171 |
73,684 |
| BURWIG SUSAN E | Exec. VP, Operations |
Oct 12 '26 |
Option Exercise |
166.73 |
3,000 |
500,190 |
70,984 |
| BURWIG SUSAN E | Exec. VP, Operations |
Oct 07 '26 |
Option Exercise |
166.73 |
2,000 |
333,460 |
67,984 |
| Troendle August J. | President & CEO |
Sep 30 '26 |
Sale |
625.47 |
21,966 |
13,739,074 |
338,225 |
| Troendle August J. | President & CEO |
Sep 29 '26 |
Sale |
621.02 |
26,701 |
16,581,855 |
360,191 |
| Troendle August J. | President & CEO |
Sep 28 '26 |
Sale |
620.07 |
2,410 |
1,494,369 |
386,892 |
| Troendle August J. | President & CEO |
Sep 25 '26 |
Sale |
620.60 |
154 |
95,572 |
389,302 |
| Troendle August J. | President & CEO |
Sep 24 '26 |
Sale |
621.33 |
27,833 |
17,293,478 |
389,456 |
| Troendle August J. | President & CEO |
Sep 23 '26 |
Sale |
628.64 |
16,083 |
10,110,417 |
417,289 |
| Troendle August J. | President & CEO |
Sep 22 '26 |
Sale |
628.11 |
49,018 |
30,788,696 |
433,372 |
1.02%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):